This article is more than 5 years old. Information may no longer be current.
Lux Biosciences completes enrollment in uveitis therapy clinical trial program
Click Here to Manage Email Alerts
JERSEY CITY, N.J. — Lux Biosciences has completed enrollment for a clinical trial program of voclosporin, a corticosteroid-sparing agent for treating noninfectious uveitis, the company announced in a press release.
Previously called LX211, Luveniq (voclosporin) is an oral form of a calcineurin inhibitor designed for treating chronic, noninfectious posterior and intermediate uveitis, the release said.
The clinical trial program — called LUMINATE (Luveniq uveitis multicenter investigation of a new approach to treatment) — includes three randomized, placebo-controlled, double-masked studies that have enrolled approximately 560 patients at 58 sites in seven countries. The trials are examining voclosporin's ability to reduce inflammation in both the anterior and posterior segments of the eye, according to the release.
Lux Biosciences is also developing voclosporin in proprietary topical formulations for other ophthalmic indications, including dry eye syndrome, other chronic inflammatory ocular surface diseases and age-related macular degeneration.
If approved, the drug will be the first steroid-sparing agent to be commercialized for uveitis in the United States, the release said.